Pharma, Biotech and Life Sciences
Demand is Infinite – How will this Effect Interim Management?
Monday, December 14th, 2009
With the end of 2009 fast approaching and a fresh New Year looming I am pleased to say that many of our clients are already starting to talk about the lifting of spending freezes and the need to increase headcount next year if long term strategies are to be brought back on track. I am [...]
Underlying Symptoms!
Wednesday, September 30th, 2009
The general consensus among interim managers in pharma and related sectors in one of subtle positivity.
It is also apparent that the issues facing many pharma companies and especially biotech businesses started long before the recession made its effects widespread. The thawing of budgets, the recommencing of change projects, integration programmes and investment in ERP systems [...]
Innovation draught causing a thawing in the interim market …..
Wednesday, August 26th, 2009
Thomas Lonngren, Head of the European Medicines Agency, the European Union’s regulator, says that since the innovation drought became clear this decade, much progress has been made through earlier and deeper consultation with industry.
He argues that the biggest barrier to progress is science itself. “We are going into a new era of drug development where [...]
Survival or growth - which strategy?
Wednesday, June 10th, 2009
Historically pharma organisations have been ‘Cash rich and organisationally poor’ however from the Global Big Pharma’s to University spinouts a mixture of the current economic climate, governmental healthcare policy and competition driven by emerging markets has put a stop to the lacklustre attitudes of the past.
Pressures on R&D and Supply chain costs are nothing [...]
